Xenon Pharmaceuticals XENE Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's change in lease liabilities?
- Xenon Pharmaceuticals (XENE) reported change in lease liabilities of -$349K in Q1 2026.
- How has Xenon Pharmaceuticals's change in lease liabilities changed year-over-year?
- Xenon Pharmaceuticals's change in lease liabilities decreased by 13.7% year-over-year, from -$307K to -$349K.
- What is the long-term trend for Xenon Pharmaceuticals's change in lease liabilities?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's change in lease liabilities has grown at a 29.3% compound annual growth rate (CAGR), from -$600K to -$1.3M.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.